New SEC Form D filing

Amani Therapeutics, Inc., 2026-10-01

A new SEC Form D private-offering notice from New York, NY, a $59,999,999 filer-stated offering target in Biotech. The source filing is one click away.

What this filing says

Amani Therapeutics, Inc. site↗ Verified via SEC Form D

Clinical-stage biotech developing AM-01, a fixed-dose combination of clozapine and a licensed novel compound for treatment-resistant schizophrenia.

New filing yesterdayFiled to raise $59,999,999First money in 2026-09-16Raised so far $34,999,999HQ (as filed) New York, NYSector Biotech web-verified against the company’s own siteStage (inferred) GrowthCall status Call-ready
Source linked the Form D on EDGAR↗Website verified amanitx.com↗Named in the filing 5 executives & directors
Open this row on the live feed →More new filings in New York →More Biotech filings →

This is a public SEC Form D private-offering notice, the filer's own statement to the SEC. Amounts are offering targets, not confirmed closes. Takeoff Radar pulls Form D nightly from EDGAR and links every filing to its source.

Other Form D filings from the same week

each with its own page and its own EDGAR source